Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions.

Marie PerretAurélie Bertaut Julie NiogretSophie MarilierPierre JouannyPatrick Manckoundia Leila Bengrine-LefevreValérie QuipourtJeremy Barben

Published in: Drugs & aging (2023)

In older patients taking ICB for solid cancers, concomitant AP may influence efficacy and concomitant PPI may influence tolerance. Further studies are needed to confirm these results.

Keyphrases

transcription factor
physical activity
community dwelling
young adults
protein protein
case control